<DOC>
	<DOCNO>NCT02947334</DOCNO>
	<brief_summary>This study Phase 3 , double blind , placebo control , randomize , stratify , parallel group , multi-center clinical trial design compare efficacy safety bococizumab 150 mg SC Q2wks placebo LDL-C lower subject primary hyperlipidemia mixed dyslipidemia high high risk CV event . The study enroll total approximately 750 subject 4 - 5 Asian countries/areas ( include China mainland ) ; approximately 600 subject sit China . Subjects randomize bococizumab treatment arm placebo arm 1:1 ratio .</brief_summary>
	<brief_title>Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects</brief_title>
	<detailed_description>After provide consent , subject enter screen period approximately 28 day verify eligibility trial . Eligible subject consider enrolled progress Randomization visit . Results screen evaluation review subject continue meet eligibility criterion randomize . Randomized subject enter 12-week treatment period , follow 40-week long-term treatment period 6 week follow-up , total 58 week ( approximately 14 month ) study participation . Subjects attend clinic visit show Schedule Activities . Subjects randomize receive either 150 mg Q2wks bococizumab placebo 1:1 ratio . Lipid level blind investigator staff , subject sponsor .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Males female age 18 year age . With primary hyperlipidemia mixed dyslipidemia . Treated stable daily dose statin At high high risk incur CV event Fasting LDLC &gt; =70 mg/dL ( 1.81 mmol/L ) subject high approve dose statin ; Fasting LDL C &gt; =77 mg/dL ( 1.99 mmol/L ) subject high approve dose . Fasting TG ≤400 mg/dL ( 4.51 mmol/L ) Prior exposure bococizumab investigational PCSK9 inhibitor NYHA class IV , Left Ventricular Ejection Fraction &lt; 25 % Poorly control hypertension History hemorrhagic stroke lacunar infarction result stroke Untreated hyperthyroidism TSH &gt; 1 × ULN Undergoing apheresis plan start apheresis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>